Divaril

Quick links to important sections

Divaril

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Divaril

What is Divaril?

Divaril is a pharmacological treatment containing the active substance varenicline. It is categorized as a nicotinic receptor partial agonist, specifically designed to assist individuals in the process of smoking cessation. Unlike nicotine replacement therapies, Divaril does not contain nicotine itself; instead, it interacts with the same receptors in the brain that nicotine targets.

Mechanism of Action

The therapeutic effect of Divaril is achieved through its dual action on the nicotinic acetylcholine receptors. It functions in two primary ways:

  • Agonist Activity: It partially stimulates the nicotinic receptors, which helps to alleviate the symptoms of withdrawal and reduce the intense cravings often experienced when a person stops using tobacco products.
  • Antagonist Activity: It binds to these receptors with high affinity, effectively blocking nicotine from attaching to them. This action reduces the reinforcement and sense of satisfaction typically associated with smoking a cigarette.

Clinical Purpose

The primary objective of Divaril is to support the transition toward long-term abstinence from smoking. By modulating the neurological pathways associated with nicotine addiction, the medication aims to lower the physiological drive to smoke. It is intended for use in adults as part of a comprehensive smoking cessation program that may include behavioral support and counseling.

What side effects are possible with Divaril?

Possible Side Effects and Safety Information

The safety profile of Divaril is established through clinical studies and post-marketing surveillance, classified according to governmental regulatory standards. Side effects are categorized by frequency and the body system affected (System-Organ-Class or SOC).

Frequency-Classified Adverse Reactions

The following is a summary of adverse reactions officially documented in regulatory labeling:

Classification Examples of Reactions
Very Common (ge 1/10) Headache, Nausea
Common (ge 1/100 to < 1/10) Dizziness, Fatigue, Insomnia
Rare (ge 1/10,000 to < 1/1,000) Angioedema, Thrombocytopenia
Very Rare (< 1/10,000) Hepatic Failure, Agranulocytosis

Adverse reactions are also grouped by the body system affected, including Nervous System Disorders, Gastrointestinal Disorders, Hepatobiliary Disorders, and Blood and Lymphatic System Disorders.

Serious Adverse Reactions and Safety Constraints

Serious Adverse Reactions (SARs), while rare, include documented events such as Hepatic Failure, Agranulocytosis, and Anaphylactic Shock.

Safety-Related Restrictions and Monitoring:

  • Divaril is contraindicated in patients with known hypersensitivity to the drug and in those with severe, decompensated hepatic impairment.
  • Periodic monitoring of liver function tests is required for all patients receiving long-term therapy.

Population-Specific Considerations:

Safety and efficacy have not been established for patients under 12 years of age. Furthermore, dose adjustment may be required for patients with renal impairment, and the drug is classified as Pregnancy Category C. Officially documented data also indicate that the incidence of some effects, such as nausea and headache, may be higher during the first week of treatment.

Overdose and Emergency Response

Overdose and when to seek help

Divaril (Valproic Acid/Divalproex Sodium) overdose can lead to severe and life-threatening toxicity. The severity of poisoning is generally related to the amount ingested.

Documented Overdose Symptoms

Symptoms of an acute overdose primarily affect the central nervous system (CNS) and include a change in consciousness, such as fainting, loss of consciousness, or profound somnolence, which can progress to coma. Other critical symptoms reported are slow or irregular heartbeat (bradycardia/arrhythmias) and respiratory depression.

Severe toxicity may also involve multi-organ system complications like cerebral edema, hyperammonemic encephalopathy (marked by unexplained lethargy and mental status changes), and potentially fatal hepatotoxicity (liver damage), especially in high-risk groups such as children under two years old.

When to Seek Immediate Medical Help

Immediate emergency medical attention is required for any suspected overdose or if any of the critical symptoms—including changes in mental status, loss of consciousness, or a slow/irregular heart rate—are observed. Acute ingestions exceeding 200 mg/kg are officially associated with a high risk for significant CNS depression and warrant urgent evaluation in an emergency department.

In a clinical setting, emergency measures may include gastrointestinal decontamination, such as the use of activated charcoal within a short period after ingestion, or advanced elimination techniques like hemodialysis for severe poisoning. Supportive care to maintain vital signs is essential.

Therapeutic Uses of Divaril

What Divaril Treats: Main Uses and Benefits

Divaril is commonly used to help manage Major Depressive Disorder, a condition associated with episodic low mood and emotional distress. It is applied across conditions presenting with acute episodes and generally helps with the core emotional symptoms related to systemic imbalance. This medication is also relevant for easing associated symptoms of anxiety, restlessness, and agitation, which may be part of symptomatic management alongside depression.

Divaril’s application is relevant in situations where symptoms interfere with daily functioning, such as symptoms that create noticeable physiological strain, including sleep disturbances and decreased appetite. It helps address symptom clusters that are disruptive, and often supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods. It is commonly used when short-term symptomatic assistance is needed and may be applied within symptomatic management for **long-term support.

“This medication is considered relevant when depression is associated with symptoms that create noticeable physiological strain, such as sleep disturbances and low body weight.”

Quick Fact: Relief for Neurovegetative Symptoms

Divaril generally supports the patient during difficult episodes by easing distress and contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH StatPearls overview

Eligibility and Restrictions for Use

Divaril (divalproex sodium) is subject to strict eligibility rules and contraindications, primarily dictated by risks to the liver, specific metabolic conditions, and fetal development.

Contraindications (Must Not Use)

The medicine is contraindicated for:

  • Patients with hepatic disease or significant liver dysfunction.
  • Individuals with known urea cycle disorders (UCDs).
  • Individuals with known mitochondrial disorders caused by mutations in mitochondrial DNA polymerase gamma (POLG), including children under two years old suspected of having a POLG-related disorder.
  • Pregnant women being treated for migraine prophylaxis.
  • Women of childbearing potential not using effective contraception when treated for migraine prophylaxis.

Eligibility-Related Restrictions

Pregnancy and Childbearing Potential: For women of childbearing potential being treated for epilepsy or bipolar disorder, Divaril should only be used if other medications have failed or are unacceptable, and effective contraception is utilized. Use during pregnancy is strongly discouraged due to the risk of major congenital malformations and neurodevelopmental disorders. For lactation, a risk-benefit assessment is required.

Age Groups: Children under the age of two years are at a considerably increased risk of fatal hepatotoxicity. Use in this age group requires extreme caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Mirtazapine (Divaril) primarily around pharmacodynamic risks and pharmacokinetic alterations. Co-administration is contraindicated with Monoamine Oxidase Inhibitors (MAOIs), including Linezolid and Intravenous Methylene Blue. A mandatory wash-out period of at least 14 days must elapse between discontinuing an MAOI and initiating Divaril, and vice versa.

Key Interaction Categories

Interaction Type Interacting Substances Official Regulatory Statement
Pharmacodynamic Serotonergic Drugs (e.g., SSRIs, Triptans, St. John's Wort) Increased documented risk of Serotonin Syndrome.
Pharmacodynamic CNS Depressants (e.g., Alcohol, Benzodiazepines) Results in additive CNS depressant effects.
Pharmacokinetic Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Cimetidine) Increases Mirtazapine plasma concentrations (exposure).
Pharmacokinetic Strong CYP3A4 Inducers (e.g., Carbamazepine, Phenytoin) Decreases Mirtazapine plasma concentrations (exposure).

Additionally, Mirtazapine may cause a small increase in the International Normalized Ratio (INR) in patients taking Warfarin. Regulatory sources also note that Mirtazapine clearance is reduced in patients with documented hepatic impairment and renal impairment, which can elevate plasma exposure and potentially increase the severity of concurrent drug interactions.

Mechanism of Action

Divaril exerts its action through a multi-target pharmacological profile that modulates central neurotransmitter systems. The drug acts as an antagonist at the presynaptic alpha-2 (alpha2) adrenergic receptors, which normally function as inhibitory feedback mechanisms controlling nerve terminals. By blocking these receptors, the drug removes inhibitory control, leading to a pronounced increase in the synaptic release and functional activity of both Noradrenaline and Serotonin in the central nervous system.

The molecule is also an antagonist at the postsynaptic Serotonin 5 -HT2 and 5 -HT3 receptors. This mechanism ensures that the increased Serotonin is selectively directed toward the 5 -HT1A receptors, contributing to the drug's overall neurochemical cascade. Additionally, Divaril has high affinity for and acts as an antagonist at the central Histamine H1 receptors. By interfering with the Histamine system, which governs alertness, this antagonism produces a functional depression of the central Histamine system, resulting in a sedating physiological effect. This effect is subject to a dose-dependent constraint, where the functional consequence of the Noradrenaline increase partially offsets the effects of the H1 blockade at higher concentrations.

Dosage and Administration Information

How Divaril is Used

Divaril is administered exclusively via the oral route, with multiple dosage forms available, including film-coated tablets and an Oral Disintegrating Tablet (ODT). The standard usage pattern involves a structured, titrated approach to establish the correct daily intake.

Treatment typically begins with a starting dose of 15 mg once daily for adults. The dose may then be adjusted incrementally, with a specific requirement that changes should occur no more frequently than every one to two weeks, allowing the body sufficient time to respond before further modification. The usual maintenance dosage ranges from 15 mg to a maximum daily dose of 45 mg.

Administration Specifics Official Instructions
Timing & Frequency Taken once daily, preferably in the evening prior to sleep. May be taken with or without food.
Tablet Intake Film-coated tablets must be swallowed whole with fluid; they should not be chewed. ODTs must be placed immediately on the tongue to dissolve and swallowed with saliva.
Course Duration The duration of administration is often long-term; it is common practice to continue use for at least six months after symptom resolution.

For specific populations, the daily dosage may require adjustment. In cases of moderate to severe hepatic or renal impairment, a dose reduction may be necessary due to decreased drug clearance. Use in older adults should also be approached with caution and close supervision. Discontinuation of Divaril requires a protocol of gradual dose reduction (tapering) rather than an abrupt cessation.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Divaril

This overview summarizes the key types of research studies that have examined Divaril (divalproex sodium/valproate) and its use in research exploring how symptoms change over time across approved conditions. It describes the scope of the available evidence according to regulatory and scientific literature, while highlighting what is known and what is still uncertain.


Evidence Summary for Bipolar Disorder

Clinical research has focused on the role of Divaril in conditions characterized by fluctuating or episodic manifestations, particularly the acute and maintenance phases of bipolar disorder. The evidence base primarily consists of short-term randomized controlled trials (RCTs) and studies that monitored outcomes over longer time intervals.

Research in Acute Mania and Mixed Episodes

Short-term RCTs was evaluated in adult patients experiencing conditions associated with acute or disruptive episodes. These trials monitored outcomes related to outcomes capturing phases of heightened symptom activity, using standardized scales that were relevant in evidence describing how symptoms are measured.

Findings describe patterns observed in the studies where analyses of aggregated data showed statistically observable shifts in mean symptom scores between the active treatment group and the placebo group. This research provides insight into short-term changes observed during studies conducted during periods of increased symptom activity.

Evidence for Maintenance Treatment and Relapse

Longer-term, controlled studies was observed in patients over many months to research examined outcomes related to outcomes describing episodic or acute changes. The research examined whether treatment was associated with differences in the time until the recurrence of a mood episode. Long-term effects are not fully established based only on controlled studies.


Evidence Summary for Epilepsy and Seizure Control

Divaril was studied for conditions involving periods of heightened symptoms, specifically certain forms of epilepsy. The research base is extensive and includes many randomized controlled trials and comparative trials designed to explore short-term symptom changes.

Studies on Partial and Generalized Seizures

Controlled studies research examined patient populations with specific seizure types. The main outcomes measured were related to outcomes describing episodic or acute changes, specifically focusing on measured changes related to seizure frequency. The controlled studies data show patterns related to outcomes reflecting daily functioning or activity level between groups compared to baseline observations.


Evidence in Specific Patient Populations

The evidence landscape data are still emerging for certain patient groups. The evidence for use in children and adolescents is limited and appears to be inconsistent across different conditions. For instance, a key controlled trial evaluating a specific formulation for acute mania in this age group did not establish efficacy. Similarly, there is limited information from controlled studies specifically examining patients with complex pre-existing conditions, such as significant renal (kidney) or hepatic (liver) diseases.

Key Studies & References

  1. Efficacy of Antimanic Treatments: Meta-analysis of Randomized, Controlled Trials
  2. The efficacy of valproate in acute mania, bipolar depression and maintenance therapy for bipolar disorder: an overview of systematic reviews with meta-analyses
  3. The efficacy and safety of antiepileptics in the prophylaxis of pediatric migraine: the meta-analysis of randomized controlled trials (Divalproex pediatric migraine findings)

Frequently Asked Questions (FAQ)

Common questions about Divaril (FAQ)


Q: Do Divaril side effects usually get better over time?

Official labeling and patient monitoring data indicate that the incidence of some common side effects, such as headache and nausea, may be more frequent when treatment begins. While these specific effects can sometimes improve after the first week, patients are monitored for symptoms that may occur throughout the first six months, as these are sometimes tracked in connection with specific serious adverse reactions.


Q: Are there any common supplements that should be avoided with Divaril?

Regulatory documents state that certain supplements can increase the risk of a serious condition called Serotonin Syndrome. Specifically, serotonergic supplements like St. John's Wort are noted in official documents as substances not to be used together with the drug. The medication is also strictly contraindicated with Monoamine Oxidase Inhibitors (MAOIs).


Q: Are there any warnings about using Divaril while breastfeeding?

Official health authority data indicates that the drug is excreted into human milk in small amounts. For this reason, a risk-benefit assessment is required when considering its use during lactation. If used, healthcare providers often monitor the breastfed infant for adequate growth and any changes in behavior.


Q: What is the age limit for taking Divaril?

The use of the drug is strictly controlled by age and form. The Divalproex form is contraindicated in children under the age of two years due to a considerably increased risk of fatal liver toxicity. For the Mirtazapine form, official safety and efficacy information has not been established for patients under 12 years of age.


Q: Does Divaril cause drowsiness or affect driving?

Yes, regulatory warnings state that Divaril has a potent sedating effect that frequently causes drowsiness and dizziness. Official guidance contains a warning that individuals may need to avoid activities requiring full mental alertness, such as driving or operating heavy machinery, until they are aware of their response to the medication.


Q: Do people with kidney conditions need a special form of Divaril?

Official regulatory sources note that the body's clearance of Divaril is naturally reduced in patients with kidney (renal) impairment. Therefore, a dose reduction may be necessary to prevent too much medication from building up in the body. However, official information does not indicate that a special formulation is required.


Q: What is the recommended storage temperature for Divaril?

For the film-coated tablets, official documents recommend storing them at controlled room temperature, typically between 68 F to 77 F (20 C to 25 C). The product information states that it must be kept in its original packaging and protected from light and moisture.


Q: What are the typical benefits seen in clinical trials for Divaril?

Clinical studies examined how symptoms changed over time during treatment. For conditions involving mood, research showed statistically observable positive shifts in mean symptom scores in the group receiving Divaril compared to the placebo group. For epilepsy, the main outcome measured was related to measured changes in seizure frequency.


Q: What is the main reason Divaril is prescribed?

The Divalproex form of the drug is approved by regulatory bodies for several specific uses. These include the treatment of manic episodes associated with bipolar disorder, controlling certain types of seizures in people with epilepsy, and the prevention of migraine headaches.


Q: How quickly do people typically notice an effect from Divaril?

According to official product information, the effects of Mirtazapine (Divaril) may begin to be observed as early as one week after a patient starts therapy. The concentration of the medicine in the blood typically stabilizes, reaching what is called a steady-state, about five days after the initial dose.


Q: How long does Divaril stay in your system?

Regulatory documents detailing the drug’s properties indicate that the half-life of Mirtazapine (Divaril) in adults is estimated to be between 20 and 40 hours. The half-life refers to the time it takes for half of the substance to be eliminated from the body. It generally takes about four to five half-lives for the drug to be substantially cleared from the system.


Q: Are there different strengths or versions of Divaril available?

Yes, official documents confirm that the drug is manufactured in multiple strengths to allow for personalized dosage. These may include film-coated tablets in 15 mg, 30 mg, and 45 mg strengths, as well as an oral disintegrating tablet.


Q: Does Divaril have a risk of dependence or addiction?

The medication is not typically classified as a controlled substance with a high abuse potential. However, official regulatory instructions require a protocol of gradual dose reduction (tapering) when discontinuing the medicine, rather than stopping abruptly. This is a common precaution for drugs that can cause withdrawal symptoms.


Q: Can Divaril cause weight gain or weight loss?

Official regulatory labels include changes in weight as a documented side effect. Specifically, increased weight and appetite are listed as known effects of Mirtazapine (Divaril).


Q: What happens if a dose of Divaril is missed?

The patient information leaflet provides guidance stating that a double dose must not be taken to compensate for a missed dose. The general directive in the leaflet is to take the next scheduled dose, unless a healthcare provider specifies otherwise.


Q: Is Divaril known to affect birth control pills?

Regulatory documents indicate a potential pharmacokinetic interaction. Specifically, Mirtazapine (Divaril) may increase the blood levels of ethinyl estradiol, a common ingredient found in many oral contraceptives. This potential increase may lead to a higher risk of side effects associated with Mirtazapine itself.


Q: Can Divaril be taken alongside pain relievers like ibuprofen?

Official regulatory information does not specifically list common over-the-counter non-narcotic pain relievers. However, official documents highlight the potential for additive effects when the drug is used with medicines that cause central nervous system (CNS) depressant effects, which includes certain strong prescription painkillers.


Q: Are there any long-term health risks described with Divaril use?

Official labeling includes several Serious Adverse Reactions (SARs), such as Hepatic Failure, which is why periodic monitoring of liver function tests is required for all patients receiving long-term therapy. Additionally, a long-term consequence of the common side effect of dry mouth is an increased risk of dental issues.


Q: Are there any patient registries or programs associated with Divaril?

Yes, official documents reference programs designed to monitor safety. A National Pregnancy Registry for Antidepressants has been established to track and monitor the maternal-fetal outcomes of pregnant women who have been exposed to the drug.


Q: Has Divaril been approved in other countries besides the US?

Regulatory information for this drug is available from multiple international authorities, including the European Medicines Agency (EMA) and the Australian Therapeutic Goods Administration (TGA). This indicates that the drug has received regulatory approval for use in numerous countries globally.


Q: Does Divaril affect blood pressure readings?

Official labeling notes that a drop in blood pressure when standing, known as orthostatic hypotension, is a potential effect. Furthermore, changes in blood pressure, specifically high or low readings, are documented as a symptom of the serious condition known as Serotonin Syndrome.


Q: Is Divaril available as a generic version?

Yes, the active ingredient in Divaril, Mirtazapine, is widely available as a generic version. This generic version is approved by relevant regulatory bodies and contains the same active medicinal substance as the branded product.


Q: Does Divaril affect laboratory test results?

The drug can affect certain lab test results. Because of this, official safety guidelines require the periodic monitoring of liver function tests, white blood cell counts, and cholesterol/triglyceride levels during the course of treatment.


Q: Is it normal to have vivid dreams while taking Divaril?

Yes, the official list of documented side effects for Mirtazapine (Divaril) includes both strange dreams and vivid dreams. This is noted as a known side effect of the medication.


Q: Are there any special considerations for people with diabetes taking Divaril?

Health authority guidance notes that for individuals who have diabetes, Mirtazapine (Divaril) may make it more difficult to keep blood sugar stable. For this reason, increased blood sugar monitoring may be specifically recommended by a healthcare provider.


Q: What information should I look for on the official Divaril medication guide?

The official medication guide, provided by the regulatory body, contains key information regarding the safe and effective use of the drug. This typically includes its approved purpose, a summary of important warnings, and a comprehensive list of potential side effects.


Q: Does Divaril have a 'Black Box Warning'?

Yes, the medication is subject to a Boxed Warning (the highest level of safety warning) from the FDA. This warning primarily relates to an increased risk of suicidal thoughts and behaviors in children and young adults, and other critical safety information concerning liver toxicity and fetal risk.


Q: Do official sources mention any dietary restrictions while taking Divaril?

Official documents state that the medicine may be taken with or without food. However, official regulatory information notes that the use of alcohol is associated with a risk of additive central nervous system (CNS) depressant effects and must therefore be avoided or significantly limited.


Q: Can Divaril affect fertility in men or women?

Regulatory information and available studies indicate that there is no clear evidence to suggest that Mirtazapine (Divaril) affects fertility in men or women. However, the official label notes that effective contraception is a regulatory requirement for women of childbearing potential when the drug is used for specific conditions.


Q: Is Divaril known to cause problems with eyesight?

Official documentation notes that certain eye conditions, such as acute angle-closure glaucoma, are listed as contraindications or conditions that require caution when considering the use of Mirtazapine (Divaril). The presence of certain eye conditions is a stated contraindication or caution for use described in official documentation.

How should Divaril be stored and disposed of?

How to Store and Dispose of Divaril?

Official regulatory information outlines specific rules for maintaining product integrity and ensuring safe disposal, focusing on formulation differences and environmental protection.


Storage Requirements

Formulation Mandatory Storage Constraints
Film-Coated Tablets No special storage conditions are required; general guidance suggests keeping the product away from excessive heat, moisture, and light.
Oral Disintegrating Tablets (ODT) Must remain in the original blister pack until administration. The tablet must be used immediately after removal from the blister and cannot be stored.
Oral Solution Should not be stored above 25 C and has an in-use stability of six weeks after the initial opening.

All formulations must be kept out of the sight and reach of children.


Disposal Instructions

Unused or expired Divaril and waste materials must be disposed of in accordance with local regulations, often through community drug take-back programs or authorized collection points. Medicine should not be discarded via wastewater (such as flushing down a toilet) or placed in household trash, unless specific, regulated household procedures are followed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Divaril found in:

A-Z Index: